Key result
Advanced chronic kidney disease linked to ~2.7-year shorter time to transcatheter heart valve re-intervention.
Why the study?
Evidence regarding whether advanced chronic kidney disease serves as an independent risk factor for shorter time to left-sided transcatheter heart valve re-intervention remains limited.
Does advanced chronic kidney disease accelerate the time to transcatheter heart valve re-intervention in patients with left-sided bioprosthetic valves?
Observational (n=271)
Does advanced chronic kidney disease accelerate the time to transcatheter heart valve re-intervention in patients with left-sided bioprosthetic valves?
Advanced chronic kidney disease and interval decline in eGFR are independently associated with an accelerated time to transcatheter heart valve re-intervention in patients with left-sided bioprosthetic valves.
Answers are grounded in this paper and cite their sources.
May support closer surveillance in advanced CKD; leaves open causal role in accelerated bioprosthetic failure.
BACKGROUND: Evidence regarding whether advanced chronic kidney disease (ACKD) serves as an independent risk factor for shorter time to valve re-intervention remains limited. OBJECTIVES: This study investigates the prognostic association between ACKD and transcatheter heart valve re-intervention (THVr) in patients with left-sided bioprosthetic valves. METHODS: We conducted a retrospective study of patients who underwent THVr between November 2011 and March 2025 following prior surgical or transcatheter bioprosthetic aortic or mitral valve replacement. Patients with estimated glomerular filtration rate (eGFR) ≤45 ml/min/1.73 m RESULTS: Among 271 THVr patients (mean age 74 ± 10 years, 57.2% males, 77.0% Caucasians), 241 underwent aortic and 30 underwent mitral valve re-intervention. ACKD was identified in 27 patients (10%). ACKD patients were younger (68.8 vs. 74.8 years, p = 0.003), more frequently African American (51.9% vs 13.9%, p < 0.01), had higher rates of prior myocardial infarction (31.6% vs 12.2%, p = 0.033), and higher Society of Thoracic Surgeons (STS) score (8.8 vs 5.5, p = 0.032). ACKD patients had a significantly shorter time to THVr (7.4 vs 10.1 years, p = 0.012). Interval decline in eGFR was independently associated with shorter time to THVr. In-hospital outcomes were similar between groups, including mortality (0% vs 0.8%; p = 1), blood transfusion (18.5% vs 10.7%, p = 0.21), any bleeding (7.4% vs 5.7%, p = 0.7), or stroke (3.7% vs 0.8%, p = 0.27). CONCLUSION: ACKD patients undergoing THVr tend to be younger and have advanced co-morbidities. The interval decline in their eGFR may be associated with accelerated time to THVr. These observational findings are hypothesis generating, suggesting a need for enhanced surveillance for early detection of valve deterioration.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2026) conducted an observational in Prior surgical or transcatheter bioprosthetic aortic or mitral valve replacement (n=271). Advanced chronic kidney disease (ACKD) vs. No advanced chronic kidney disease was evaluated on time to transcatheter heart valve re-intervention (THVr) (p=0.012). Advanced chronic kidney disease was associated with a significantly shorter time to transcatheter heart valve re-intervention compared to those without ACKD (7.4 vs 10.1 years, p=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: